Simplify Logo

Full-Time

Process Engineer

Formulation Development

Confirmed live in the last 24 hours

Editas Medicine

Editas Medicine

201-500 employees

Develops CRISPR-based gene editing therapies

Hardware
Biotechnology
Healthcare

Senior, Expert

Cambridge, MA, USA

Category
Biology Lab & Research
Biology & Biotech
Requirements
  • Bachelor’s degree in Chemical Engineering, Biomedical Engineering, Chemistry, Pharmaceutical Sciences, or related discipline
  • 6+ years of relevant experience or Master’s with 4+ years of experience
  • Strong technical expertise in mRNA/LNP formulation development
  • Proficient UFDF/Dialysis operation skills
  • Working knowledge of downstream purification techniques
  • Experience in molecular biology and microbial manufacturing
  • Experience in Technical Transfer of cGMP manufacturing processes
Responsibilities
  • Lead or support experiments for RNP, mRNA/LNP manufacturing process definition
  • Support technology transfer of mRNA/LNP manufacturing process
  • Collaborate with AD to generate data for formulation studies
  • Provide technical support for engineering and cGMP manufacturing campaigns
  • Document all experimental work in an electronic lab notebook
  • Cross-train personnel on processes
  • Maintain abreast latest industry trends for RNP, LNP, and nucleic acid-based process

Editas Medicine is a leader in the biotechnology industry, focused on developing cutting-edge CRISPR gene editing technologies to create transformative medicines for serious diseases. This focus places the company at the forefront of genetic research and therapy development, providing a dynamic and pioneering environment for its employees. As a workplace, it promises a culture of constant learning and innovation, ideal for those passionate about advancing healthcare and contributing to vital medical breakthroughs.

Company Stage

IPO

Total Funding

$884.6M

Headquarters

Cambridge, Massachusetts

Founded

2013

Growth & Insights
Headcount

6 month growth

19%

1 year growth

24%

2 year growth

13%